# Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function

> **NCT07751250** · PHASE1 · RECRUITING · sponsor: **Arcus Biosciences, Inc.** · enrollment: 16 (estimated)

## Conditions studied

- Healthy Participants
- Hepatic Impairment

## Interventions

- **DRUG:** Casdatifan

## Key facts

- **NCT ID:** NCT07751250
- **Lead sponsor:** Arcus Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-14
- **Primary completion:** 2027-05
- **Final completion:** 2027-05
- **Target enrollment:** 16 (ESTIMATED)
- **Last updated:** 2026-09-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07751250

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07751250, "Comparative PK Assessment Study of Casdatifan in Moderate Hepatically Impaired Participants Versus Matched Participants With Normal Hepatic Function". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07751250. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*